endpoint & Cmed’s New Integration
endpoint Clinical, the global interactive response technology (IRT) company, and Cmed Technology, the technology division of a full-service CRO with its encapsia clinical data suite, announced a new interoperability in their clinical trial software systems. This integration allows the power of IRT to be accessed through eSource.
The new technology offering was designed by connecting endpoint’s technology platforms, PULSE and DRIVE, with Cmed’s new dedicated web app, Inventory, furthering the scope of its third generation clinical data suite encapsia.
As the complexities of clinical trials steadily increase, endpoint and Cmed are dedicated to enhance their technologies further to minimize the burden on site staff and provide them with an optimal “consumer-like” experience.
For more information , www.endpointclinical.com
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
